{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-skin/prescribing-information/topical-antifungals/","result":{"pageContext":{"chapter":{"id":"216d1aaa-ae60-548d-b753-0c53f672a4ad","slug":"topical-antifungals","fullItemName":"Topical antifungals","depth":2,"htmlHeader":"<!-- begin field a86a41e1-97ff-41c0-89cd-9b626dc27f01 --><h2>What do I need to know about prescribing topical antifungals?</h2><!-- end field a86a41e1-97ff-41c0-89cd-9b626dc27f01 -->","summary":"","htmlStringContent":"<!-- begin item bd8991f0-9d46-460b-897f-bf60dbdddad9 --><!-- begin field d67d25d6-760d-4c40-b017-47ed2d7445e8 --><h3>Topical imidazoles</h3><ul><li><strong>Clotrimazole </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">ABPI Medicines Compendium, 2015a</a>]<ul><li>Clotrimazole 1% cream is licensed for the treatment of all dermatomycoses due to yeasts (<em>Candida </em>species).</li><li>It should be applied to the affected area 2–3 times a day and continued for at least 2 weeks. </li><li>Adverse effects include:<ul><li>Local skin irritations, such as rash, pruritus, oedema, and skin peeling.</li><li>Damage to latex contraceptives —<strong> </strong>advise the person that clotrimazole may cause damage to latex contraceptives and can inactivate spermicidal contraceptives. Alternative contraceptive precautions should be used during treatment with (and for at least 5 days after stopping) topical clotrimazole.</li></ul></li></ul></li><li><strong>Miconazole </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">ABPI, 2015a</a>]<ul><li>Miconazole 2% cream is licensed for the treatment of mycotic infections of the skin and nails. </li><li>It should be applied to the affected area twice a day and continued for 10 days after all skin lesions are healed.</li><li>Adverse effects include:<ul><li>Damage to latex contraceptives — advise the person that topical miconazole may cause damage to latex contraceptives and can inactivate spermicidal contraceptives. Alternative contraceptive precautions should be used during treatment with (and for at least 5 days after stopping) topical miconazole.</li></ul></li><li>Miconazole, including the topical formulations, can enhance the anticoagulant effect of warfarin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">MHRA, 2016</a>].<ul><li>If miconazole and warfarin are used concurrently, monitor the anticoagulant effect of warfarin; if necessary, reduce the dose of warfarin.</li><li>Advise the person to seek medical advice if they notice signs of over-anticoagulation during concurrent treatment, such as sudden unexplained bruising, nosebleeds, or blood in the urine.</li></ul></li></ul></li><li><strong>Econazole </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">ABPI, 2015b</a>]<ul><li>Econazole 1% cream is licensed for the treatment of fungal infections of the skin.</li><li>It should be applied to the affected area twice a day and continued until all skin lesions are healed.</li><li>Adverse effects include:<ul><li>Damage to latex contraceptives —<strong> </strong>advise the person that topical econazole may cause damage to latex contraceptives and can inactivate spermicidal contraceptives. Alternative contraceptive precautions should be used during treatment with (and for at least 5 days after stopping) econazole.</li></ul></li><li>Systemic econazole is known to interact with oral anticoagulants. Due to the limited systemic availability of topical preparations, clinically relevant interactions are rare; however, the manufacturer of econazole advises that caution should be exercised (and anticoagulant effect should be monitored) during concurrent use with an oral anticoagulant.</li></ul></li><li><strong>Ketoconazole (for people aged 18 years and older) </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">ABPI Medicines Compendium, 2015b</a>]<ul><li>Ketoconazole 2% cream is licensed for the treatment of cutaneous candidosis in adults.</li><li>It should be applied to the affected area once or twice a day and continued for a few days after all skin lesions are healed.</li><li>Adverse effects include local skin irritations, such as rash and pruritus.<ul><li>The effect of topical ketoconazole on latex contraceptives is unknown.</li></ul></li><li>No drug interaction studies have been performed.</li></ul></li></ul><p><strong>Terbinafine (for adults only) </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">ABPI Medicines Compendium, 2016a</a>]</p><ul><li>Terbinafine 1% cream is licensed for the treatment of yeast infections of the skin, especially those caused by the genus <em>Candida</em>.</li><li>It should be applied thinly to the affected area once or twice a day for 14 days.</li><li>Adverse effects include local skin irritations, such as rash, burning sensation, and pruritus.<ul><li>These symptoms must be distinguished from hypersensitivity reactions, such as widespread pruritus, rash, bullous eruptions, and hives, which are reported in sporadic cases and require discontinuation of treatment with terbinafine.</li></ul></li><li>There are no known drug interactions with terbinafine cream.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">BNF 72, 2016</a>]</p><!-- end field d67d25d6-760d-4c40-b017-47ed2d7445e8 --><!-- end item bd8991f0-9d46-460b-897f-bf60dbdddad9 -->","topic":{"id":"0d4d1ca9-1f95-59a6-9163-91faf2fce35e","topicId":"44d93cc7-56e9-4f35-92ee-6fe5c97d5646","topicName":"Candida - skin","slug":"candida-skin","lastRevised":"Last revised in May 2017","chapters":[{"id":"fdd77154-68fd-5e12-ab34-4980d82ec2e8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"20e27b79-2755-56d0-811f-79d59b1ad973","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"dc171785-2e5e-50c2-9f57-0cd56c75a2d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"9ce37f9c-5801-5953-acaa-da119b97818f","slug":"changes","fullItemName":"Changes"},{"id":"a9f51671-bb82-536e-9b5f-c98cb41291e6","slug":"update","fullItemName":"Update"}]},{"id":"6f439137-5e54-571e-b7aa-8cce9c5c58f6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7433f221-a6d1-5f98-a53d-32009abd6d65","slug":"goals","fullItemName":"Goals"},{"id":"c1df0f9d-1fa3-5aa3-96a3-7636250c141a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1edcd62f-0185-5317-a25a-afb5e18d3d5e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e514a54c-ae49-5bb6-9c8e-0de16f244409","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"00336847-83a8-540e-954e-23801c8eb472","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"99dacab6-3fed-5a48-ad05-74876122fa41","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7884dd9b-ba26-56fe-8b96-29022de73f28","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3aa00866-7e3b-5a84-9b01-091a915acd1e","slug":"definition","fullItemName":"Definition"},{"id":"82ae2b5c-db02-50a0-9572-a12b245c9f9f","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"16b02723-03c7-5877-8f98-955d9ba0adda","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"3e942288-d611-5acc-a0a5-79c5a9bbf5c3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"815a9379-3ee5-585a-997e-8daf2e138d95","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"556293f9-6cf5-5f40-bdd2-06dfff1c5b82","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d48752d8-0979-5908-b55c-40d0bf50e947","fullItemName":"Management","slug":"management","subChapters":[{"id":"187d27a6-4a3a-59f4-99c1-33a221ca0d2b","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ab1b23e6-6d8b-5003-bdea-20df2a09e2b1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"216d1aaa-ae60-548d-b753-0c53f672a4ad","slug":"topical-antifungals","fullItemName":"Topical antifungals"},{"id":"a6376d8b-e282-52b4-a990-ceb7d73afaf3","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"}]},{"id":"1b822a63-5645-5cdc-9a82-7e61da577351","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6bcfeaf8-f78c-5867-99f3-adb4fde508db","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"e9a0750e-9090-547a-aac2-eea9118c16c8","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7624a8b0-8f03-5842-b47f-0374a546f628","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e3980da9-5b2b-5ebb-a7ed-7edcff958155","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3941da5-da7c-5313-b272-7df5b0bd2985","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0839e574-758e-59d0-8520-6335161c5e49","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3603b783-48c3-58d3-a191-1fb1ff30eca8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ab1b23e6-6d8b-5003-bdea-20df2a09e2b1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}